About denosumab
RANKL inhibitor; monoclonal antibody
Used for
- Treats osteoporosis in people at increased fracture risk
- Treats bone loss caused by certain cancer treatments
- Reduces fracture risk in men receiving androgen-deprivation therapy
Usual adult dose
60 mg by injection under the skin every 6 months for osteoporosis or treatment-related bone loss.
Usual dose in children
For giant cell tumor of bone in adults and skeletally mature adolescents: 120 mg under the skin every 4 weeks, with extra doses during the first month.
Common side effects
- Back, muscle, or joint pain
- Skin infections, including cellulitis
- Low blood calcium
- Eczema or rash
Important warnings
- Correct low calcium and ensure adequate calcium and vitamin D; severe low calcium can occur.
- Do not stop or delay without a treatment plan; stopping can cause multiple spinal fractures.
- Jawbone damage and unusual thigh fractures are rare risks.
- Do not use in pregnancy; severe allergic reactions can occur.
Pregnancy
May harm a developing baby. Pregnancy testing and effective contraception are recommended during treatment and for at least 5 months after the last dose.
Breastfeeding
It is unknown whether denosumab passes into human milk. Discuss treatment and breastfeeding with a healthcare professional.
Interactions
- Other medicines that lower calcium may increase the risk of low blood calcium.
- Medicines that suppress the immune system may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.